Reviewing Cytocore (OTCMKTS:MDIT) & SI-Bone (OTCMKTS:SIBN)

Cytocore (OTCMKTS:MDIT) and SI-Bone (NASDAQ:SIBN) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk.

Analyst Recommendations

This is a summary of recent recommendations and price targets for Cytocore and SI-Bone, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cytocore 0 0 0 0 N/A
SI-Bone 0 0 4 0 3.00

SI-Bone has a consensus target price of $24.75, suggesting a potential upside of 22.65%. Given SI-Bone’s higher possible upside, analysts plainly believe SI-Bone is more favorable than Cytocore.

Profitability

This table compares Cytocore and SI-Bone’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cytocore N/A N/A N/A
SI-Bone N/A N/A N/A

Institutional and Insider Ownership

38.9% of SI-Bone shares are held by institutional investors. 85.4% of Cytocore shares are held by insiders. Comparatively, 38.8% of SI-Bone shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares Cytocore and SI-Bone’s revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Cytocore $6.81 million 0.38 -$6.81 million N/A N/A
SI-Bone $55.38 million 8.95 -$17.45 million ($0.71) -28.42

Cytocore has higher earnings, but lower revenue than SI-Bone.

Summary

SI-Bone beats Cytocore on 5 of the 7 factors compared between the two stocks.

Cytocore Company Profile

MEDITE Cancer Diagnostics, Inc. operates as a medical technology company. It develops, manufactures, and markets molecular biomarkers, medical devices, and consumables for the detection, risk assessment, and diagnosis of cancerous and precancerous conditions and related diseases. The company offers USE 33, an ultrasonic decalcification instrument that automatically runs the process under controlled temperatures; TPC 15 Duo and Trio, a tissue processing instrument; TES 99 and TES Valida cooling units; and M530, A550, M380 microtomes for tissue sectioning. It also provides M630, a freezing microtome; TST44, a robotic multi-staining system; COT 20, a linear staining system; and RCM 9000, ACS 720, and TWISTER robotic coverslippers. In addition, the company develops SoftKit device for the self-collection of a sample that can be evaluated to provide an assessment of the health of the entire female genital tract. It sells its products through direct sales and distributors in the United States, China, Europe, and North Africa. The company serves histology and cytology laboratories associated with hospitals or research institutions, and independent laboratories. MEDITE Cancer Diagnostics, Inc. is headquartered in Orlando, Florida.

SI-Bone Company Profile

SI-BONE, Inc., a medical device company, develops and commercializes a proprietary minimally invasive surgical implant system in the United States and Internationally. It offers iFuse, an implant system to fuse the sacroiliac joint to treat sacroiliac joint dysfunction that causes lower back pain. The company was founded in 2008 and is headquartered in Santa Clara, California.

Receive News & Ratings for Cytocore Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytocore and related companies with MarketBeat.com's FREE daily email newsletter.